Modified immunoglobulins for targeting amyloid deposits
US12030934B2 · kind B2 · utility
3Cited by
16References
30Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Mar 9, 2023 |
| Grant date | Jul 9, 2024 |
| Priority date | — |
| Expiry date | Mar 9, 2043 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2319/33
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Provided herein are modified immunoglobulins comprising an amyloid reactive peptide joined to an antibody, as well as humanized antibodies that bind to human amyloid fibrils and antibody-peptide fusion proteins. Also provided herein are methods of treating amyloid-based diseases by administering a modified immunoglobulin, humanized antibody, or antibody-peptide fusion protein.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.